Newsroom

LOS ANGELES--(BUSINESS WIRE)--XTIA Investors Have Opportunity to Lead XTI Aerospace, Inc. Securities Fraud Lawsuit with SBS Law...

SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becomes Hims. Patients will maintain the treatment plans and provider relationships they rely on, n...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus brand to transition to the Hims brand. Australia represents a mean...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scien...

LAS VEGAS--(BUSINESS WIRE)--Sphere Entertainment Co. (NYSE: SPHR) announced today that The Wizard of Oz at Sphere will debut a series of new and expanded 4D effects beginning Friday, September 25th, 2026. In addition, tickets for The Wizard of Oz at Sphere are now on sale through the beginning of 2027 at thesphere.com. Since opening in August 2025, Sphere has brought the beloved classic, The Wizard of Oz at Sphere, to life at an unprecedented scale by using advanced proprietary technologies. Th...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against XTI Aerospace, Inc. ("“XTI Aerospace” or the “Company”) (NASDAQ: XTIA) and reminds investors of the October 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. T...

BARRANQUILLA, Colombia--(BUSINESS WIRE)--Naturmega, an advanced lipid science company specializing in omega-3 and next-generation lipid technologies, will introduce SUPRIAX2™ to the North American market at SupplySide Global 2026 in Las Vegas. The ingredient is the first market-ready solution within Naturmega’s BeyondKrill™ territory, reflecting the company’s vision for the next frontier of omega-3 innovation: moving beyond source and concentration toward intentional lipid design.For decades, om...

LISBON, Portugal--(BUSINESS WIRE)--Oxy Capital SGOIC, S.A. has published its comments on the decision of the Chair of the Independent Board to adjourn ICG’s Scheme Meeting and EGM from 28 August to 10 September 2026 in order to solicit additional proxies in favour of the MBO Bid. The stated rationale is difficult to accept when weeks earlier the Independent Board had defended the timetable as being governed by the Irish Takeover Rules. That apparently inflexible position was reversed after the...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- BeOne Medicines Ltd.（Nasdaq：ONC、HKEX：06160、SSE：688235）は、グローバルなオンコロジー企業であり、HER2陽性（HER2+）の局所進行性または転移性胃食道腺がん（GEA）の一次治療として、ZIIHERA®（ザニダタマブ）と化学療法の併用（TEVIMBRA®（チスレリズマブ）併用および非併用）を評価する第3相HERIZON-GEA-01試験の第2回中間解析（IA2）で、良好なトップライン結果が得られたことを発表しました。IA2では、ZIIHERAと化学療法の併用は、トラスツズマブと化学療法の併用と比較して、全生存期間（OS）について統計学的に有意かつ臨床的に意義のある改善を示し、本試験の残る主要評価項目を達成しました。 IA2ではまた、TEVIMBRA、ZIIHERAおよび化学療法の併用レジメンについて、より長期の追跡データが得られ、OSのハザード比が改善し、治療効果の持続が認められるとともに、概ね管理可能な安全性プロファイルが示されました。これ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis’ favor. The appellate court upheld the District Court's decision that three patents covering...